Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin
- PMID: 7604808
- DOI: 10.1016/s0002-9149(05)80026-8
Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin
Abstract
Alcohol consumption is known to have beneficial effects on cardiac mortality, probably by increasing high density lipoprotein cholesterol (HDL-C). Alcohol also increases triglycerides and, in some studies, total cholesterol and low density lipoprotein cholesterol (LDL-C). Nothing is known, however, of the effects of alcohol on the pharmacokinetics and efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Consequently, 2 studies have been carried out to determine the effects of alcohol consumption on the pharmacokinetics and efficacy of the HMG-CoA reductase inhibitor fluvastatin. Firstly, the effects of acute alcohol consumption on a single, oral 40 mg dose of fluvastatin were examined in a reference-controlled, randomized, crossover study in 10 healthy volunteers. Measurements were made after ingestion of 70 g of ethanol diluted to 20% with lemonade and, following a 7-day period, after ingestion of lemonade alone (reference). The half-life (t1/2) of a single dose of fluvastatin was significantly reduced by acute alcohol consumption compared with reference, whereas the area under the time-concentration curve (AUC), peak concentration (Cmax), and time to peak concentration (tmax) did not differ from the reference group. The lipid profile, measured 8 hr after administration, did not differ significantly from baseline in the reference group, apart from a slight reduction in apolipoprotein (apo)-AI. Triglyceride levels increased with alcohol, probably due to impaired fatty acid oxidation. Surprisingly, total cholesterol and LDL-C fell significantly, possibly due to altered pharmacokinetics, as reflected by the lower t1/2.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.Am J Cardiol. 1995 Jul 13;76(2):129A-135A. doi: 10.1016/s0002-9149(05)80035-9. Am J Cardiol. 1995. PMID: 7604788 Clinical Trial.
-
Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.Am J Cardiol. 1995 Jul 13;76(2):65A-70A. doi: 10.1016/s0002-9149(05)80021-9. Am J Cardiol. 1995. PMID: 7604802 Clinical Trial.
-
Effects of alcohol and fluvastatin on lipid metabolism and hepatic function.Ann Intern Med. 1995 May 1;122(9):678-80. doi: 10.7326/0003-4819-122-9-199505010-00006. Ann Intern Med. 1995. PMID: 7702230 Clinical Trial.
-
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.Drugs. 1996 Mar;51(3):433-59. doi: 10.2165/00003495-199651030-00011. Drugs. 1996. PMID: 8882381 Review.
Cited by
-
Pharmacokinetic interactions between alcohol and other drugs.Clin Pharmacokinet. 1997 Aug;33(2):79-90. doi: 10.2165/00003088-199733020-00001. Clin Pharmacokinet. 1997. PMID: 9260032 Review.
-
Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases.BMJ Open. 2020 Aug 13;10(8):e039034. doi: 10.1136/bmjopen-2020-039034. BMJ Open. 2020. PMID: 32792452 Free PMC article.
-
Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of scottish men with 21 years of follow up.BMJ. 1999 Jun 26;318(7200):1725-9. doi: 10.1136/bmj.318.7200.1725. BMJ. 1999. PMID: 10381706 Free PMC article.
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Clinical pharmacokinetics of fluvastatin.Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003. Clin Pharmacokinet. 2001. PMID: 11368292 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical